Biomet starts tennis elbow trial
This article was originally published in Clinica
Executive Summary
Biomet Biologics has completed enrolment of 230 patients in the trial of its Recover platelet separation kit. This kit processes a sample of a patient's blood to produce autologous platelet-rich plasma to treat chronic lateral epicondylitis, also known as tennis elbow. The randomised, double-blind trial is being performed under a US FDA-approved Investigational Device Exemption (IDE) and is expected to conclude in mid-2011. Study participants will receive either the Biomet treatment or the local anaesthetic bupivacaine. The researchers will assess adverse events, severity of pain and arm function. The data from this pivotal study will support an approval submission to the US FDA. Biomet Biologics is a subsidiary of Warsaw, Indiana-based Biomet.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.